...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in microbiology >Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time
【24h】

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

机译：研究药物抗药性并建立体外药敏性断裂点的药效学：准备黄金时间

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Considerable advancements have been made in providing informative, relevant interpretations of the results of antimicrobial susceptibility tests to clinicians, clinical microbiologists, epidemiologists, and researchers. At the same time, the science of pharmacokinetics has flourished, and the importance of drug exposure in vivo on outcome is now recognized by researchers and clinicians alike. More recently, pharmacokinetic and quantitative measures of antimicrobial susceptibility have been integrated using pharmacokinetic-pharmacodynamic (PK-PD) models to forecast clinical and microbiological outcomes. Stochastic methods utilizing patient population pharmacokinetics, target organism minimum inhibitory concentration (MIC) distributions, and PK-PD targets from non-clinical models of infection or clinical data have established a new paradigm for determining in vitro susceptibility breakpoints and selection of empirical therapy in clinical practice. Given the increasing problem of antimicrobial resistance, these new tools are valuable additions for clinicians, researchers, and regulatory authorities.
机译：在向临床医生，临床微生物学家，流行病学家和研究人员提供抗菌药敏感性试验结果的信息性，相关解释方面取得了相当大的进步。同时，药代动力学的科学蓬勃发展，研究人员和临床医生都认识到体内药物暴露对预后的重要性。最近，已使用药代动力学-药效学（PK-PD）模型整合了抗药性的药代动力学和定量测量方法，以预测临床和微生物学结果。利用患者群体药代动力学，靶标生物最低抑菌浓度（MIC）分布以及非临床感染模型或临床数据中的PK-PD靶标的随机方法建立了确定体外药敏性断点和选择临床经验疗法的新范例实践。鉴于日益增加的抗菌素耐药性问题，这些新工具为临床医生，研究人员和监管机构提供了宝贵的补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号